Compile Data Set for Download or QSAR
Report error Found 4050 with Last Name = 'heine' and Initial = 'n'
TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195118(US9212153, 178,Ex. 139 | US10336717, Compound 178)
Affinity DataIC50: 0.600nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195118(US9212153, 178,Ex. 139 | US10336717, Compound 178)
Affinity DataIC50: 0.600nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195133(US9212153, 193,Ex. 154 | US10336717, Compound 193)
Affinity DataIC50: 0.800nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195133(US9212153, 193,Ex. 154 | US10336717, Compound 193)
Affinity DataIC50: 0.800nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195132(US9212153, 192,Ex. 153 | US10336717, Compound 192)
Affinity DataIC50: 0.960nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195132(US9212153, 192,Ex. 153 | US10336717, Compound 192)
Affinity DataIC50: 0.960nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195123(US9212153, 183,Ex. 144 | US10336717, Compound 183)
Affinity DataIC50: 1nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195123(US9212153, 183,Ex. 144 | US10336717, Compound 183)
Affinity DataIC50: 1nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM403903(US10336717, Compound 180)
Affinity DataIC50: 1.10nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195379(US9212153, 463,Ex. 397 | US10336717, Compound 463)
Affinity DataIC50: 1.10nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195120(US9212153, 180,Ex. 141)
Affinity DataIC50: 1.10nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195379(US9212153, 463,Ex. 397 | US10336717, Compound 463)
Affinity DataIC50: 1.10nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM404165(US10336717, Compound 465)
Affinity DataIC50: 1.20nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195378(US9212153, 465,Ex. 399 | US9212153, 462,Ex. 396 | ...)
Affinity DataIC50: 1.20nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM113278(US8633212, 56 | US9212153, 56 | US10336717, Compou...)
Affinity DataIC50: 1.40nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195378(US9212153, 465,Ex. 399 | US9212153, 462,Ex. 396 | ...)
Affinity DataIC50: 1.40nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195316(US9212153, 394,Ex. 335)
Affinity DataIC50: 1.40nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195378(US9212153, 465,Ex. 399 | US9212153, 462,Ex. 396 | ...)
Affinity DataIC50: 1.40nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195117(US9212153, 177,Ex. 138 | US10336717, Compound 177)
Affinity DataIC50: 1.5nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195117(US9212153, 177,Ex. 138 | US10336717, Compound 177)
Affinity DataIC50: 1.5nMpH: 4.4Assay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM404041(US10336717, Compound 334 | US10336717, Compound 33...)
Affinity DataIC50: 1.70nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195521(US9212153, 334,Ex. 282)
Affinity DataIC50: 1.70nMpH: 4.4Assay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195128(US9212153, 188,Ex. 149 | US10336717, Compound 188)
Affinity DataIC50: 1.90nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM156246(US9018391, 8)
Affinity DataIC50: 1.90nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2015
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195128(US9212153, 188,Ex. 149 | US10336717, Compound 188)
Affinity DataIC50: 1.90nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195093(US9212153, 142,Ex. 107 | US10336717, Compound 142)
Affinity DataIC50: 2nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM111911(US8623901, 239)
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195093(US9212153, 142,Ex. 107 | US10336717, Compound 142)
Affinity DataIC50: 2nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM113298(US8633212, 76 | US9212153, 76 | US10336717, Compou...)
Affinity DataIC50: 2.10nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195520(US9212153, 246,Ex. 199 | US10336717, Compound 245)
Affinity DataIC50: 2.10nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetIsoform C of Beta-secretase 1 (BACE-I-457)(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM113298(US8633212, 76 | US9212153, 76 | US10336717, Compou...)
Affinity DataIC50: 2.10nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity. The assay was performed at room temperature in 96-well...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2014
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM113298(US8633212, 76 | US9212153, 76 | US10336717, Compou...)
Affinity DataIC50: 2.10nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195519(US9212153, 245,Ex. 199 | US10336717, Compound 246)
Affinity DataIC50: 2.10nMpH: 4.4Assay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM403872(US10336717, Compound 147)
Affinity DataIC50: 2.20nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM404041(US10336717, Compound 334 | US10336717, Compound 33...)
Affinity DataIC50: 2.20nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195392(US9212153, 478,Ex. 409 | US10336717, Compound 478)
Affinity DataIC50: 2.20nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195501(US9212153, 147,Ex. 111)
Affinity DataIC50: 2.20nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195522(US9212153, 335,Ex. 282)
Affinity DataIC50: 2.20nMpH: 4.4Assay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195392(US9212153, 478,Ex. 409 | US10336717, Compound 478)
Affinity DataIC50: 2.20nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195506(US9212153, 99,Ex. 65 | US10336717, Compound 99)
Affinity DataIC50: 2.40nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195536(US9212153, 522,Ex. 420 | US10336717, Compound 523)
Affinity DataIC50: 2.40nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195506(US9212153, 99,Ex. 65 | US10336717, Compound 99)
Affinity DataIC50: 2.40nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195403(US9212153, 523,Ex. 420 | US10336717, Compound 522)
Affinity DataIC50: 2.40nMpH: 4.4Assay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195418(US9212153, 1 | US10336717, Compound 1)
Affinity DataIC50: 2.60nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195119(US9212153, 179,Ex. 140 | US10336717, Compound 179)
Affinity DataIC50: 2.60nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195127(US9212153, 187,Ex. 148 | US10336717, Compound 187)
Affinity DataIC50: 2.60nMAssay Description:For each compound being tested, the BACE activity was monitored in a fluorescence quenching assay (FRET) using the ectodomain of BACE (aa 1-454) fuse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetIsoform C of Beta-secretase 1 (BACE-I-457)(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM113223(US8633212, 1)
Affinity DataIC50: 2.60nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity. The assay was performed at room temperature in 96-well...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2014
Entry Details
US Patent

TargetBeta-secretase 1(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM156243(US9018391, 5)
Affinity DataIC50: 2.60nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2015
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195418(US9212153, 1 | US10336717, Compound 1)
Affinity DataIC50: 2.60nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

TargetBeta-secretase 1 [1-458](Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM195119(US9212153, 179,Ex. 140 | US10336717, Compound 179)
Affinity DataIC50: 2.60nMpH: 4.5 T: 2°CAssay Description:Inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE activity using commercially available substrate HiLyte Fluor 488...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2016
Entry Details
US Patent

Displayed 1 to 50 (of 4050 total ) | Next | Last >>
Jump to: